Volume 23, Number 1—January 2017
CME ACTIVITY - Research
Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–20121
This activity has been planned and implemented through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; and (4) view/print certificate.
Release date: December 14, 2016; Expiration date: December 14, 2017
Upon completion of this activity, participants will be able to:
1. Identify rates of invasive candidiasis (IC)–associated hospitalizations in the United States from 2002–2012, based on an analysis of inpatient hospitalization records from the Healthcare Cost and Utilization Project
2. Determine risk factors for IC-associated hospitalizations in the United States from 2002–2012
3. Assess healthcare utilization and costs of IC-associated hospitalizations in the United States from 2002–2012.
Thomas J. Gryczan, MS, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Thomas J. Gryczan, MS, has disclosed no relevant financial relationships.
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships: owns stock, stock options, or bonds from Pfizer.
Disclosures: Sara Strollo, MPH; Michail S. Lionakis, MD, MSc; Jennifer Adjemian, PhD; Claudia A. Steiner, MD, MPH; and D. Rebecca Prevots, PhD, MPH, have disclosed no relevant financial relationships.>
- Page created: December 14, 2016
- Page last updated: December 14, 2016
- Page last reviewed: December 14, 2016
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)